布地奈德福莫特罗联合噻托溴铵吸入粉雾剂治疗慢性阻塞性肺疾病合并支气管哮喘的效果

Effect of Budesonide Formoterol Combined with Tiotropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease with Bronchial Asthma

目的:探讨布地奈德福莫特罗吸入粉雾剂联合噻托溴铵吸入粉雾剂治疗在慢性阻塞性肺疾病(COPD)合并支气管哮喘(简称哮喘)患者中的应用价值。方法:选取2019年1月—2022年12月苏北人民医院收治的COPD合并哮喘患者80例为研究对象,采用随机数字表法分为对照组和观察组,各40例。对照组进行异丙托溴铵和孟鲁司特治疗,观察组进行布地奈德福莫特罗吸入粉雾剂和噻托溴铵吸入粉雾剂治疗。比较两组临床疗效、哮喘控制试验(ACT)与COPD患者自我评估测试(CAT)评分、肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)]、急性加重情况、不良反应。结果:观察组临床疗效总有效率高于对照组,差异有统计学意义(P=0.023);治疗后,观察组ACT评分高于对照组,CAT评分低于对照组,差异有统计学意义(P<0.05);治疗后,观察组FVC、FEV1水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组急性加重次数少于对照组,急性发作间隔时间长于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:布地奈德福莫特罗吸入粉雾剂联合噻托溴铵吸入粉雾剂治疗COPD合并哮喘的效果显著,可改善患者ACT、CAT评分,促进肺功能指标恢复,减少急性加重次数、延长发作间隔时间,且用药安全性良好。

Objective:To investigate the application value of budesonide formoterol inhalation powder and tiotropium bromide inhalation powder in the treatment of chronic obstructive pulmonary disease(COPD)complicated with bronchial asthma(asthma for short).Methods:A total of eighty patients with COPD combined with asthma admitted to Subei People's Hospital from January 2019 to December 2022 were selected as the study objects,and were divided into control group and observation group by random number table method,with forty patients in each group.The control group was treated with ipratropium bromide and Montelukast,and the observation group was treated with budesonide formoterol inhalation powder and tiotropium inhalation powder.The clinical efficacy,asthma control test(ACT)and COPD patient self-assessment test(CAT)scores,pulmonary function indicators[forced vital capacity(FVC),forced expiratory volume in the first second(FEV1)],acute exacerbations and adverse reactions were compared between the two groups.Results:The total effective rate of clinical curative effect of the observation group was higher than that of the control group,and the difference was statistically significant(P=0.023);after treatment,the ACT score of observation group was higher than that of control group,and the CAT score was lower than that of control group,the difference was statistically significant(P<0.05);after treatment,FVC and FEV1 levels in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05);after treatment,the number of acute exacerbations in the observation group was less than that in the control group,and the interval of acute attacks was longer than that in the control group,the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Budesonide formoterol inhaled powder aerosol combined with tiotropium bromide in the treatment of COPD complicated with asthma has a significant effect,which can improve ACT and CAT scores of patients,promote the recovery of pulmonary function indicators,reduce the number of acute exacerbations,prolong the interval of attacks,and has a good safety.